Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6

Stem Cells

Volumn 20, Issue 2, 2002, Pages 119-138

  Viswanathan, Sowmya ^a   Benatar, Tania ^a   Rose John, Stefan ^b   Lauffenburger, Doug A ^c   Zandstra, Peter W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF KIEL   (Germany)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Embryonic stem cells; Gp130; LIF; Ligand receptor signaling complexes; Self renewal; Thresholds

Indexed keywords

ALKALINE PHOSPHATASE; CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; LEUKOCYTE MIGRATION INHIBITION FACTOR; STAGE SPECIFIC EMBRYO ANTIGEN 1; TRANSCRIPTION FACTOR; UVOMORULIN;

ANIMAL CELL; ARTICLE; CELL FATE; CELL RENEWAL; CONCENTRATION RESPONSE; EMBRYO CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; LIGAND BINDING; NONHUMAN; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STEM CELL; STOICHIOMETRY;

ANIMALIA;

EID: 0036219910     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.20-2-119     Document Type: Article

References (91)

1. Embryonic stem cell lines derived from human blastocysts
2. Derivation of pluripotent stem cells from cultured human primordial germ cells
3. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro
4. From the cover: Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells
5. Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells
6. Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo
7. Distinct requirements for optimal growth and In vitro expansion of human CD34(+)CD38(-) bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells
8. Cytokine manipulation of primitive human hematopoietic cell self-renewal
9. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells
10. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides
11. Leukemia inhibitory factor (LIF) concentration modulates embryonic stem cell selfrenewal and differentiation independently of proliferation
12. A ligand-receptor signaling threshold model of stem cell differentiation control: A biologically conserved mechanism applicable to hematopoiesis
13. Establishment in culture of pluripotential cells from mouse embryos
14. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells
15. Interleukin-6 and soluble interleukin-6 receptor: Direct stimulation of gp130 and hematopoiesis
16. gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells
17. Maintenance of the pluripotential phenotype of embryonic stem cells through direct activation of gp130 signalling pathways
18. Leukemia inhibitory factor sustains the survival of mouse primordial germ cells cultured on TM4 feeder layers
19. Effect of Steel factor and leukaemia inhibitory factor on murine primordial germ cells in culture
20. Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture
21. Functional requirement of gp130-mediated signaling for growth and survival of mouse primordial germ cells in vitro and derivation of embryonic germ (EG) cells
22. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo
23. Are LIF and related cytokines functionally equivalent?
24. Ciliary neurotrophic factor maintains the pluripotentiality of embryonic stem cells
25. Oncostatin M (OSM) inhibits the differentiation of pluripotent embryonic stem cells in vitro
26. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways
27. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
28. Molecular cloning and expression of an IL-6 signal transducer, gp130
29. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase
30. LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor
31. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130
32. The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor
33. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells
34. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins
35. Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1)
36. Developmental stage-specific antigens during mouse embryogenesis
37. Alkaline phosphatase activity in mouse teratoma
38. Alkaline phosphatase activity in the preimplantation mouse embryo
39. A system regulating alkaline phosphatase activity in the duodenum of the chick embryo and mouse
40. The in vitro development of blastocyst-derived embryonic stem cell lines: Formation of visceral yolk sac, blood islands and myocardium
41. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies
42. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector
43. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture
44. Expression of catenins during mouse embryonic development and in adult tissues
45. Synthesis and phosphorylation of uvomorulin during mouse early development
46. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4
47. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells
48. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion
49. Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities
50. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6
51. Developmentally programmed induction of differentiation inhibiting activity and the control of stem cell populations
52. Isolation and characterization of a leukemia inhibitory factor-independent embryonic stem cell line
53. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction
54. Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells
55. Inter-species chimeras of leukaemia inhibitory factor define a major human receptor-binding determinant
56. Conversion of the biological specificity of murine to human leukemia inhibitory factor by replacing 6 amino acid residues
57. Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists
58. The family of the IL-6-type cytokines: Specificity and promiscuity of the receptor complexes
59. IL-6 type cytokine receptor complexes: Hexamer, tetramer or both?
60. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation
61. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130
62. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling
63. Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells
64. Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution
65. The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand
66. Receptor clustering on a cell-surface. I. Theory of receptor cross-linking by ligands bearing two chemically identical functional groups
67. Quantitative insight into proliferation and differentiation of oligodendrocyte type 2 astrocyte progenitor cells in vitro
68. Evidence for a differential avidity model of T cell selection in the thymus
69. Positive and negative thymocyte selection induced by different concentrations of a single peptide
70. Responses of embryonic Xenopus cells to activin and FGF are separated by multiple dose thresholds and correspond to distinct axes of the mesoderm
71. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
72. Multiple regions within the cytoplasmic domains of the leukemia inhibitory factor receptor and gp130 cooperate in signal transduction in hepatic and neuronal cells
73. Distinct roles for leukemia inhibitory factor receptor alpha-chain and gp130 in cell type-specific signal transduction
74. Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells
75. The distribution of colony-forming cells among spleen colonies
76. A stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells
77. Self-renewal of hemopoietic stem cells during mixed colony formation in vitro
78. Investigations of a stochastic model of haemopoiesis
79. Stochastic branching model for hemopoietic progenitor cell differentiation
80. A stochastic model of selfrenewal and commitment to differentiation of the primitive hemopoietic stem cells in culture
81. Stochastic model revisited
82. Essential role of STAT3 for embryonic stem cell pluripotency
83. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis
84. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
85. STAT3 activation is sufficient to maintain an undifferentiated state of monse embryonic stem cells
86. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3
87. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling
88. Rational design of potent antagonists to the human growth hormone receptor
89. Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding
90. Structure of an extracellular gp130 cytokine receptor signaling complex
91. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines